Invesco Biotechnology & Genome ETF Rating $82.15 0.00 (0.00%) As of 05/22/2026 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestBuy This Stock Invesco Biotechnology & Genome ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.PBE Aggregate RatingModerate Buy 2.63Holdings in PBE have an aggregate rating of Moderate Buy based on 411 analyst ratings issued in the past year covering 25 companies (89.8% of the portfolio).PBE Aggregate Price Target$82.15High Prediction$82.15Average Prediction$82.15Low Prediction$82.15Holdings in PBE have an aggregate price target of $82.15 and a range of $82.15 to $82.15 covering 25 companies (89.8% of the portfolio).PBE Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy1 Buy rating(s)Moderate Buy18 Moderate Buy rating(s)Hold6 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Invesco Biotechnology & Genome ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 PBE Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings6.03%UTHRUnited Therapeutics$568.433.9188 of 5 stars2.85$619.42 9.0%13Insider Trade5.85%ILMNIllumina$144.413.247 of 5 stars2.28$137.75 -4.6%184.87%INCYIncyte$97.164.6313 of 5 stars2.41$104.00 7.0%22Positive News4.87%BIIBBiogen$193.763.8302 of 5 stars2.52$215.62 11.3%294.54%ALNYAlnylam Pharmaceuticals$297.454.7134 of 5 stars2.85$463.13 55.7%26Positive News4.48%GILDGilead Sciences$134.364.6253 of 5 stars2.86$156.93 16.8%29Trending NewsAnalyst RevisionGap Down4.39%AMGNAmgen$339.303.8912 of 5 stars2.48$355.19 4.7%31Positive NewsAnalyst Upgrade4.26%REGNRegeneron Pharmaceuticals$638.884.6352 of 5 stars2.70$792.65 24.1%273.60%TGTXTG Therapeutics$38.874.3336 of 5 stars2.57$52.50 35.1%73.57%CPRXCatalyst Pharmaceuticals$31.263.8178 of 5 stars2.63$32.17 2.9%8Negative News3.50%VCYTVeracyte$45.031.9399 of 5 stars2.38$44.83 -0.4%8News CoverageInsider Trade3.35%ARWRArrowhead Pharmaceuticals$74.952.49 of 5 stars2.75$87.80 17.1%123.26%NBIXNeurocrine Biosciences$156.703.8214 of 5 stars2.83$185.90 18.6%23Analyst Forecast3.23%RPRXRoyalty Pharma$54.504.0029 of 5 stars3.00$53.71 -1.4%73.19%PTGXProtagonist Therapeutics$99.192.7595 of 5 stars2.88$115.21 16.2%16Gap Up3.17%BCRXBioCryst Pharmaceuticals$8.292.6878 of 5 stars2.75$20.70 149.7%123.05%EXELExelixis$50.152.3828 of 5 stars2.39$47.35 -5.6%23Insider Trade3.03%CDNACareDx$21.631.6549 of 5 stars2.00$25.00 15.6%62.84%PTCTPTC Therapeutics$68.813.6873 of 5 stars2.57$88.36 28.4%14Positive News2.71%HALOHalozyme Therapeutics$68.323.987 of 5 stars2.50$80.67 18.1%12Positive News2.56%VCELVericel$34.733.59 of 5 stars2.50$55.40 59.5%82.43%IONSIonis Pharmaceuticals$75.563.4789 of 5 stars2.90$100.90 33.5%212.40%TBPHTheravance Biopharma$16.373.3547 of 5 stars2.75$21.83 33.4%82.35%ACADACADIA Pharmaceuticals$21.104.0525 of 5 stars2.75$31.63 49.9%162.29%RGENRepligen$115.063.493 of 5 stars2.87$166.15 44.4%15 This page (NYSEARCA:PBE) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invesco Biotechnology & Genome ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Invesco Biotechnology & Genome ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
